Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years or following 3 doses in women aged 15–25 years, for up to 3 years (HPV-070 study) and up to 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Folschweiller, Nicolas, Behre, Ulrich, Dionne, Marc, Durando, Paolo, Esposito, Susanna, Ferguson, Linda, Ferguson, Murdo, Hillemanns, Peter, McNeil, Shelly A, Peters, Klaus, Ramjattan, Brian, Schwarz, Tino F, Supparatpinyo, Khuanchai, Suryakirian, Pemmaraju V, Janssens, Michel, Moris, Philippe, Decreux, Annabelle, Poncelet, Sylviane, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500548/
https://www.ncbi.nlm.nih.gov/pubmed/30715452
http://dx.doi.org/10.1093/infdis/jiy743
Descripción
Sumario:This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9–14 years or following 3 doses in women aged 15–25 years, for up to 3 years (HPV-070 study) and up to 5 years (HPV-048 study) after the first vaccination. Both schedules elicited antibodies against HPV-31 and HPV-45 up to 5 years after first dose. The antibody concentration was similar in young girls as compared to women. Specific CD4(+) T-cell and B-cell responses to HPV-31 and HPV-45 at month 36 were similar across groups. Clinical trials registration: NCT01381575 and NCT00541970.

Ejemplares similares